Pfizer Inc (PFE) 30.41 $PFE
With Tips From Pfizer, AbbVie Lands the Biggest Pharma Deal of the Year: StockTwits
at The Street - Tue Jul 15, 7:49PM CDT
AbbVie has learned some of the lessons of the M&A business, offering a huge premium for Shire, but for a very good reason.
Why Is Wall Street Bullish on These 3 Stocks?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Rising institutional ownership combined with a low short interest are probably a couple of good signs that Wall Street thinks a stock has strong upside potential. Even so, it's not always entirely clear why the Street is bullish on a particular...
Why TheStreet Ratings Team Rates Pfizer (PFE) Stock a 'Buy'
at The Street - Tue Jul 15, 2:43PM CDT
TheStreet Ratings team reiterates its "buy" rating on Pfizer (PFE) with a ratings score of B+.
Most active New York Stock Exchange-traded stocks
AP - Tue Jul 15, 12:20PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Tue Jul 15, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Jul 15, 9:56AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Johnson & Johnson Beats on Q2 Earnings, Ups View Again - Analyst Blog
Abhijit Ghosh - Zacks Investment Research - Tue Jul 15, 9:55AM CDT
J&J's pharma segment put in a strong performance again with recently launched hepatitis C treatment Olysio boosting sales.
Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
M2 - Tue Jul 15, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mstbv/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA. Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA. The report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Competitive Analysis of Marketed Products - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Types - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/5m..._pva_drugs
Absorption Systems Announces License Agreement with Pfizer Inc.
PR Newswire - Tue Jul 15, 7:00AM CDT
Absorption Systems, a leader in novel test systems for drug transporters, announces a license agreement with Pfizer Inc., in which Pfizer will in-license Absorption Systems' BCRP-MDCK cells. This cell line is stably transfected with the human ABCG2 gene, which codes for a protein known as BCRP (breast cancer resistance protein).
Why Kandi Technologies Shot Higher and Apollo Group Fell After Hours
Jeremy Bowman, The Motley Fool - Motley Fool - Mon Jul 14, 9:00PM CDT
Stocks kicked off the week with a bang thanks to a strong report from Citigroup and more M&A deals in the health-care sector. The Dow Jones Industrial Average finished back above 17,000, gaining 112 points, or 0.7%, to finish at 17,055,...
AbbVie's Deal for Shire Benefits Investors in More Ways Than One
at The Street - Mon Jul 14, 3:40PM CDT
Upon completion of this deal, AbbVie's stock should head toward the $70 level in the next 12 to 18 months, representing gains of close to 30%.
Pfizer (PFE) Approaches New Upside Target of $30.32
Comtex SmarTrend(R) - Mon Jul 14, 9:03AM CDT
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $30.00 today and have reached the first resistance level of $30.19. Should the shares continue to rise, the resistance pivots of $30.32 and $30.64 will be of interest.
Shire Opens Door to Takeover by AbbVie
at The Street - Mon Jul 14, 8:08AM CDT
Irish drugs maker Shire said it had entered detailed discussions with suitor AbbVie about a fifth takeover proposal after eliciting a sweetened bid that values its stock at $54 billion.
Johnson & Johnson Earnings: Can Pharma Keep Stoking Growth?
Dan Caplinger, The Motley Fool - Motley Fool - Mon Jul 14, 6:00AM CDT
On Tuesday, Johnson & Johnson will release its quarterly report, and shareholders have been pleased with the stock's ascent to all-time record levels recently. Despite Johnson & Johnson having a wide array of health-care-related businesses...
Johnson & Johnson Prescribes Healthy Returns Without M&A or Breakup
at The Street - Sun Jul 13, 7:32PM CDT
'Bigger' only for the sake of getting bigger makes no sense. Not trusting management of the company to execute the business is the worst blunder of them all.
Tax Inversions: Why Are They So Popular?
Dan Caplinger, The Motley Fool - Motley Fool - Sun Jul 13, 7:05AM CDT
Recently, Medtronic and Covidien became the latest pair of companies to consider a high-value merger. One of the big motivations for these international mergers is the opportunity to do a tax inversion. But what exactly is a tax inversion, and...
Abbott, Nestle, Prepare to Profit from China���s Upcoming Baby Boom
at The Street - Fri Jul 11, 1:44PM CDT
The one-child policy has been relaxed, giving makers of baby formula and incubators more opportunities to make money
With Tips From Pfizer, AbbVie Lands the Biggest Pharma Deal of the Year: StockTwits
at The Street - Tue Jul 15, 7:49PM CDT
AbbVie has learned some of the lessons of the M&A business, offering a huge premium for Shire, but for a very good reason.
Why Is Wall Street Bullish on These 3 Stocks?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 15, 4:00PM CDT
Rising institutional ownership combined with a low short interest are probably a couple of good signs that Wall Street thinks a stock has strong upside potential. Even so, it's not always entirely clear why the Street is bullish on a particular...
Why TheStreet Ratings Team Rates Pfizer (PFE) Stock a 'Buy'
at The Street - Tue Jul 15, 2:43PM CDT
TheStreet Ratings team reiterates its "buy" rating on Pfizer (PFE) with a ratings score of B+.
Most active New York Stock Exchange-traded stocks
AP - Tue Jul 15, 12:20PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
Midday Glance: Pharmaceuticals companies
AP - Tue Jul 15, 12:20PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Tue Jul 15, 9:56AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Johnson & Johnson Beats on Q2 Earnings, Ups View Again - Analyst Blog
Abhijit Ghosh - Zacks Investment Research - Tue Jul 15, 9:55AM CDT
J&J's pharma segment put in a strong performance again with recently launched hepatitis C treatment Olysio boosting sales.
Global Postmenopausal Vaginal Atrophy Drugs Market 2014-2018 with Actavis, Novo Nordisk, Pfizer & Shionogi & Co. Dominating
M2 - Tue Jul 15, 8:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mstbv/global_pva_drugs) has announced the addition of the "Global PVA Drugs Market 2014-2018" report to their offering. The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA. Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA. The report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Actavis plc - Novo Nordisk A/S - Pfizer Inc. - Shionogi & Co. Ltd. Other Prominent Vendors - ANI Pharmaceuticals Inc. - Bionovo Inc. - EndoCeutics Inc. - QuatRx Pharmaceutical Co. - PeP-Tonic Medical AB - Teva Pharmaceutical Industries Ltd. - Therapeutics MD Inc. - Upsher-Smith Laboratories Inc. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Competitive Analysis of Marketed Products - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Types - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/5m..._pva_drugs
Absorption Systems Announces License Agreement with Pfizer Inc.
PR Newswire - Tue Jul 15, 7:00AM CDT
Absorption Systems, a leader in novel test systems for drug transporters, announces a license agreement with Pfizer Inc., in which Pfizer will in-license Absorption Systems' BCRP-MDCK cells. This cell line is stably transfected with the human ABCG2 gene, which codes for a protein known as BCRP (breast cancer resistance protein).
Why Kandi Technologies Shot Higher and Apollo Group Fell After Hours
Jeremy Bowman, The Motley Fool - Motley Fool - Mon Jul 14, 9:00PM CDT
Stocks kicked off the week with a bang thanks to a strong report from Citigroup and more M&A deals in the health-care sector. The Dow Jones Industrial Average finished back above 17,000, gaining 112 points, or 0.7%, to finish at 17,055,...
AbbVie's Deal for Shire Benefits Investors in More Ways Than One
at The Street - Mon Jul 14, 3:40PM CDT
Upon completion of this deal, AbbVie's stock should head toward the $70 level in the next 12 to 18 months, representing gains of close to 30%.
Pfizer (PFE) Approaches New Upside Target of $30.32
Comtex SmarTrend(R) - Mon Jul 14, 9:03AM CDT
Shares of Pfizer (NYSE
FE) have bullishly opened above the pivot of $30.00 today and have reached the first resistance level of $30.19. Should the shares continue to rise, the resistance pivots of $30.32 and $30.64 will be of interest. Shire Opens Door to Takeover by AbbVie
at The Street - Mon Jul 14, 8:08AM CDT
Irish drugs maker Shire said it had entered detailed discussions with suitor AbbVie about a fifth takeover proposal after eliciting a sweetened bid that values its stock at $54 billion.
Johnson & Johnson Earnings: Can Pharma Keep Stoking Growth?
Dan Caplinger, The Motley Fool - Motley Fool - Mon Jul 14, 6:00AM CDT
On Tuesday, Johnson & Johnson will release its quarterly report, and shareholders have been pleased with the stock's ascent to all-time record levels recently. Despite Johnson & Johnson having a wide array of health-care-related businesses...
Johnson & Johnson Prescribes Healthy Returns Without M&A or Breakup
at The Street - Sun Jul 13, 7:32PM CDT
'Bigger' only for the sake of getting bigger makes no sense. Not trusting management of the company to execute the business is the worst blunder of them all.
Tax Inversions: Why Are They So Popular?
Dan Caplinger, The Motley Fool - Motley Fool - Sun Jul 13, 7:05AM CDT
Recently, Medtronic and Covidien became the latest pair of companies to consider a high-value merger. One of the big motivations for these international mergers is the opportunity to do a tax inversion. But what exactly is a tax inversion, and...
Abbott, Nestle, Prepare to Profit from China���s Upcoming Baby Boom
at The Street - Fri Jul 11, 1:44PM CDT
The one-child policy has been relaxed, giving makers of baby formula and incubators more opportunities to make money
